Clinical Trials: A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m + Amifostine With Melphalan 200mg/m + Amifostine

Sponsor and Collaborators

Fred Hutchinson Cancer Research Center

National Cancer Institute (NCI)

Contacts

Michael C. C. Lill, MD

310-423-2997

lillm@cshs.org

Gordon L. Phillips, MD

585-273-4399

Sundar Jagannath, MD

888-442-2623

sjaganna@salick.com

Kathy Lilleby

206-667-5836

Thomas R. Chauncey, MD, PhD

206-764-2709

Principal Investigator

William I. Bensinger, MD,Fred Hutchinson Cancer Research Center

ClinicalTrials.gov Identifier

NCT00217438

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs